Advertisement
Advertisement
U.S. markets close in 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Immuron Limited (IMC.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.12500.0000 (0.00%)
At close: 4:10PM AEDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1250
Open0.1300
Bid0.1250 x 3350000
Ask0.1300 x 10984500
Day's Range0.1250 - 0.1300
52 Week Range0.1250 - 0.2900
Volume361,129
Avg. Volume227,867
Market Cap28.406M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for IMC.AX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    • GlobeNewswire

      IMM-124E – Demonstrates Antiviral T-Cell Immunity

      Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19 MELBOURNE, Australia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic pro

    • GlobeNewswire

      Immuron Director resignation

      MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today received the resignation of Mr Peter Anastasiou. Mr Anastasiou joined the Board in May 2015 after becoming a major shareholder in 2013 and was appointed Vice Executive Chairman in August 2015 to assist US market development opport

    • GlobeNewswire

      Immuron planned Acquisition of R&D Vaccine Company

      MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today would like to provide shareholders and the market with an update to our market announcements of 8 June 2021 and 7 July 2021. The Company has been pursuing a major acquisition of a private biotechnology company focused on the devel

    Advertisement
    Advertisement